In Acute Leukemia With Heavily Pretreated Patients, Menin Inhibitor Yields 63 Percent ORR.

Published Date: 15 Dec 2023

FDA is now reviewing the experimental medication revumenib for KMT2A-rearranged disease.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer research in the US is world class. With the government pulling out, its future is uncertain

2.

Could AI plus lasers help catch very early breast cancers?

3.

New PET tracer enables same-day imaging of triple-negative breast and urothelial cancers

4.

Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy

5.

A pilot study investigates a novel strategy for lowering anxiety and enhancing post-stem cell transplant quality of life.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot